编者按 借用毕马威《2025年中国宠物市场报告》的话：在"悦己经济"与"情感消费"崛起的宏观背景下，宠物经 济正以不可忽视的增速重塑中国宠物消费市场格局。2024年，我国城镇宠物（犬猫）消费市场规模超过 3000亿元，预计至2027年有望突破4000亿元。宠物正逐步从"功能性伴侣"向"家庭成员"的角色转变，反 映出我国宠物经济具有强劲的增长潜力。 不可否认，宠物消费市场规模不断增长。尤其是近两年，一场围绕宠物的消费升级，正蔓延到方方面 面：宠物走进越来越多的商场，越来越多的养宠人选择带宠物一起旅游、给宠物拍写真、让宠物健身上 学…… 相对于宠物食品、宠物医疗等传统行业，一些关于宠物的新兴行业也不断涌现，所有和"人"相关的生意 都正在"宠物"身上重做一遍。近日，《每日经济新闻》记者聚焦宠物经济新蓝海，看养宠人如何带"毛 孩子"过国庆中秋长假，并推出系列报道；记录下这些新服务形态折射出的中国家庭结构与情感满足方 式变迁，以及在这一过程中涌现的机遇、挑战与无限可能。 抢不到票，根本抢不到票。国庆中秋长假前夕，9月27日至30日，北京到杭州连续4天的宠物托运都没有 票了，北京到上海的热门车次也显示，宠物托运仓位已满。 ...

Group 1 - The core viewpoint of the article is the strategic collaboration between Huaxi Bio (688363.SH) and Beijing Sails Pharmaceutical Technology Co., Ltd. in various fields including new veterinary drugs, innovative medical devices, and pet health [1] - The partnership aims to launch multiple clinically needed and high-tech innovative products over the coming years [1] - This collaboration is expected to contribute to the rapid development of the pet medical industry [1]

人民财讯9月30日电，记者获悉，9月30日，华熙生物与北京塞尔斯医药科技有限公司(简称"塞尔斯医 药")联合宣布，双方在新兽药、创新医疗（002173）器械及宠物大健康等多个领域达成战略合作。未来 数年，双方将合作推出多款临床急需且具备高科技创新属性的产品，助力宠物医疗行业快速发展。 ...

Summary of the Pet Medical Industry Conference Call Industry Overview - The pet market in China is expanding, with the urban dog and cat consumption market expected to exceed 300 billion yuan in 2024, with an average annual spending of over 2,000 yuan per pet driven by demographic changes, single economy, aging population, and consumption upgrades [1][2] Key Drivers of Pet Medical Market - The pet medical market is primarily driven by: - Aging pets, with 27% of dogs and 18% of cats over 6 years old, incurring annual medical costs of 2,400 yuan, double that of younger pets [3][4] - Expansion of disease spectrum requiring more specialized treatments [4] - Increased awareness of preventive medicine, with a significant rise in vaccine and deworming product consumption [4] Growth of Pet Hospitals - The number of pet hospitals in China has significantly increased from 13,000 in 2014 to 34,000 in 2024, with a slowdown in growth rate observed in recent years [5] - The expansion is more pronounced in lower-tier cities, with first-tier cities showing a 12% growth rate, while new first-tier, second-tier, and third-tier cities have growth rates of 17% and over 20% respectively [5][7] - The chain rate of pet hospitals has increased from 5% in 2017 to 25% in 2024 [5] Competitive Landscape - The market share of leading chain veterinary hospitals remains low, with the top three brands (New Ruipeng, Ruipai, and New Rui Rui Chen) holding only 7% of the market [6] - Increased competition has led these top institutions to enhance their customer acquisition capabilities [6] Current Challenges in the Industry - Overall customer spending per visit has slightly decreased, while the profit margin has narrowed, with the loss ratio increasing to 26% [8] - The industry faces significant challenges, including a shortage of qualified veterinary professionals [8] Characteristics of Pet Owners - The pet owner demographic is becoming younger and more professional, with a focus on high-quality care and a willingness to invest in their pets' health [9] - Pet owners are increasingly informed and expect high standards in veterinary services [9] Regulatory and Economic Support - The development of the pet medical industry is supported by policies, capital investment, and a favorable economic environment [10] - The introduction of regulations has improved industry standards and reduced the shortage of veterinary medicines [10] Future Trends - The pet medical market is expected to evolve towards standardization, specialization, digitalization, and localization [11] - Addressing the needs of aging pets and the last-mile issues in lower-tier markets will be crucial for future growth [11] Notable Companies to Watch - Companies with core competencies in preventive medicine and elderly pet care, such as Ruipeng Bio, and those excelling in R&D like Keqian Bio, Laike Bio, and Zhongmu Bio, are recommended for attention [13]

Core Insights - The report highlights the significant growth potential in the pet medical market, driven by increasing pet ownership and the aging of pets, with a projected market size of 549 billion yuan by 2024 and a potential growth to 1,011 billion yuan by 2030 [10][12] - The report emphasizes the advantages of nationwide chain pet medical institutions in terms of medical technology and platform management, which are crucial for providing comprehensive services and maintaining competitive advantages [13][14] - The report identifies key players in the domestic pet medical market, including New Ruipeng, Ruipai, and Ruichen, which are establishing a competitive landscape with a focus on operational quality and efficiency [14] Company-Specific Insights - Weixinno has signed an investment cooperation agreement with Kunshan Weixin to establish a global new display industry innovation center project with a total investment of approximately 5 billion yuan [4] - Dongshan Precision is planning to issue H shares and list on the Hong Kong Stock Exchange, with discussions ongoing with relevant intermediaries [4] - Hualing Cable intends to acquire control of Anhui San Bamboo Intelligent Technology Co., which produces connectors for high-end applications [4] - Postal Savings Bank announced the absorption and merger of its wholly-owned subsidiary, optimizing its management and business structure [4] - Wolker Materials has approved an investment of up to 1 billion yuan for a new materials project in Jiangsu Province [4] Industry Insights - The report discusses the ongoing trend of "anti-involution" in the express delivery industry, which has led to a decrease in the practice of competing on price, resulting in a noticeable increase in single-ticket revenue for companies like Shentong and Yunda [6][7] - The express delivery industry is experiencing a slowdown in volume growth, with a year-on-year increase of 12.3% in August, indicating a shift towards service quality over price competition [6][8] - The report anticipates that the anti-involution policies will continue to positively impact industry profitability and stock prices, particularly for leading companies like Zhongtong and Yuantong [8]

Core Views - The report highlights the significant growth potential in the pet medical service market, driven by increasing pet ownership and the aging of pets, with a projected market size of 549 billion yuan by 2024 and a potential of 1,854 billion yuan if full coverage is achieved [6][7] - The report emphasizes the importance of national chain models in the pet medical industry, noting that the current chain rate is around 21.1%, which has room for improvement compared to the US market's 30% [7][10] - The competitive landscape is characterized by major players such as New Ruipeng, Ruipai, and Ruichen, indicating a stable market structure with a focus on operational quality and efficiency [7][10] Industry Overview - The pet medical industry is positioned at the downstream of the pet industry chain, directly interacting with pets and their owners, providing a range of services from vaccinations to surgeries [5] - The report forecasts a compound annual growth rate (CAGR) of 10.68% for the pet medical market, with expectations of reaching 1,011 billion yuan by 2030 if the pet population continues to grow at 1.5% [6][7] - The report identifies the core competencies of national chain pet medical institutions in terms of medical technology and platform management, which are crucial for providing comprehensive services and maintaining competitive advantages [8][9] Company Insights - Baoli International plans to invest in Nanjing Hongtai Semiconductor Technology Co., Ltd., reflecting confidence in the semiconductor testing equipment sector [4] - Xinda Biologics received approval for a new drug application for a diabetes treatment, indicating growth opportunities in the biopharmaceutical sector [4] - New Xiangwei's subsidiary is increasing its stake in a tech company focused on AI, showcasing strategic investments in high-growth areas [4] - Junhua Technology is expected to positively impact its financial performance through a significant procurement project with the State Grid Corporation [4]

Investment Rating - The report maintains a "Positive" outlook on the agriculture, forestry, animal husbandry, and fishery industry, specifically focusing on the pet medical sector [2]. Core Insights - The pet medical market is expected to grow significantly, driven by increasing pet ownership, pet aging trends, and the humanization of pets, leading to a projected market size of 549.4 billion yuan by 2024 [5][31]. - The report emphasizes that the national chain model is the optimal approach for pet medical services, with a current chain rate of approximately 21.1%, indicating room for growth compared to the US market's 30% [6][37]. - The competitive advantage of national chain pet medical institutions lies in their technological capabilities and platform management, which enhance their operational efficiency and profitability [7][47]. Summary by Sections 1. Pet Medical Market Potential - The pet medical market is poised for rapid growth, with a potential market size of 1,011 billion yuan by 2030, assuming a 1.5% annual growth rate in pet numbers and a 50% penetration rate [5][35]. - The increase in pet ownership and the aging of pets are expected to expand the consumer base for pet medical services [19][30]. 2. Chain Model Advantages - As of September 2024, there are over 22,000 pet medical institutions in China, with a significant portion still being single-location hospitals, indicating a potential for increased chain development [6][37]. - The report identifies three major players in the national chain pet medical market: New Ruipeng, Ruipai, and Ruichen, which dominate the competitive landscape [8][42]. 3. Technological and Management Competitiveness - The report highlights that technological capabilities are fundamental to the success of pet medical institutions, with high-quality diagnostic equipment being essential for effective treatment [48]. - Platform management, including supply chain efficiency and cost control, is crucial for enhancing profitability and scalability in the pet medical sector [7][47]. 4. Talent Development and Shortages - The pet medical industry faces a structural shortage of qualified veterinary professionals, which poses challenges for growth and service quality [53][71]. - National chain institutions are implementing comprehensive talent development programs to attract and retain skilled professionals, ensuring a high standard of care [62][71].

Core Insights - The pet economy is experiencing rapid growth, with the urban pet consumption market projected to reach 300.2 billion yuan in 2024, reflecting a 7.5% increase [1] - The demand for pet food and supplies is high, but consumer trust is low, leading to significant quality concerns [3][12] Market Overview - The pet food market is expected to grow to 155.7 billion yuan, with a modest increase of 4.6%, while the cat food market is projected to reach 144.5 billion yuan, growing by 10.7% [1] - A survey indicates that 84.68% of respondents purchased pet food in the past year, with a monthly spending range of 300 to 499 yuan being the most common [2] Consumer Concerns - Nearly 50% of pet food consumers identify quality instability as a core issue, with concerns about ingredient authenticity and expiration dates [3][5] - In the pet supplies sector, 42.52% of respondents feel that prices do not match quality, and 40.06% report that products do not align with pet behavior, increasing health risks [3] Service Quality Issues - In pet hospitals and clinics, only 50% have professional staff, raising concerns about service quality [2][9] - Among pet boarding services, only 16.25% of consumers reported no issues during their pet's stay, with common problems including behavioral changes and weight loss [7] Regulatory and Industry Challenges - The industry faces a lack of stringent regulations, with no specific legislation for pet food safety and inadequate standards for medical and burial services [12][13] - There is a significant talent gap in the industry, with a shortage of qualified veterinary professionals and a lack of standardized training and certification [13] Recommendations for Improvement - The Jiangsu Consumer Protection Committee suggests establishing mandatory national standards for pet food and supplies, enhancing service quality, and improving management systems [13] - Companies are encouraged to focus on research and development rather than solely on marketing, ensuring transparency in product claims [12][13]

Group 1 - The company, Ruipeng Biotech (300119), announced on September 12 that it will provide information regarding the operation of Ruipeng Pet Hospital through official channels only [1]

Core Viewpoint - The pet medical industry is a core sector of the pet economy, characterized by both rigidity and growth potential, following a development path similar to human consumption structure, transitioning from "goods to services" [2] Demand Side: Growth Potential in Penetration Rate and Average Spending - The aging of pets is leading to an increase in disease incidence, which is expected to trigger a surge in demand for pet medical services. The shorter lifespan of pets compared to humans means that changes in age structure will result in more pronounced demand shifts [3] - The significant growth in the penetration rate of prescription pet food reflects the rapid dissemination of pet medical knowledge in China. Prescription pet food, which is a "functional diet" prescribed by veterinarians for specific diseases, is increasingly being recognized by pet owners, especially during illness or recovery periods [3] Expansion Phase: Balancing Scale and Profitability - The domestic pet medical market is characterized by small revenue size and weak profitability. According to the 2023 China Pet Medical Industry White Paper, 82% of pet hospitals in China have annual revenues below 2.4 million yuan, and 71% have profit margins below 10%, with 26% currently operating at a loss [4] - Drawing from the U.S. market experience, while profitability is under pressure during the expansion phase, measures such as controlling the pace of expansion, standardized mergers and acquisitions, and refined operations can gradually enhance profitability [4] Cost Structure: Challenges in Variable Cost Optimization - In the domestic market, employee and procurement costs are the main constraints on optimizing variable costs for pet hospitals. The operating costs are primarily concentrated in labor and consumables, with a shortage of veterinary talent and low domestic procurement rates for consumables being significant challenges [5] - The long-term reliance on imports for veterinary vaccines and the dominance of foreign brands in pet medications contribute to higher procurement costs for domestic pet medical enterprises. In contrast, the U.S. has a mature local supply chain, which provides cost advantages in consumable procurement [5]